DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Adjunct A/Prof Patrick Emanuel, Dermatopathologist, Clínica Ricardo Palma, Lima, Peru. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley. Copy edited by Gus Mitchell. September 2018.
New therapies targeting BRAF and MEK have emerged as the key component for the treatment of BRAF-mutant metastatic melanoma.
In melanoma treated with targeted BRAF and MEK therapy, the histopathology usually shows evidence of extensive regression with numerous melanophages and inflammatory cells within areas which previously housed melanoma (figures 1,2).
Given the extensive melanin deposition and inflammation, it can be difficult to appreciate viable residual melanoma. Bleaching the section can help reduce this difficulty. Immunohistochemistry with Sox-10 can help identify residual melanoma.
It is important to have the correct clinical context and a history of targeted therapy. Without this history, the histopathology could precisely resemble natural regression in melanoma or regression of other tumours such as pigmented basal cell carcinoma or other pigmented lesions.
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.